Canbas Co., Ltd.

Canbas Co., Ltd. is a Japanese drug-discovery biopharmaceutical company dedicated to the research and development of anticancer agents. The company is headquartered in Numazu, Shizuoka Prefecture, and is listed on the Tokyo Stock Exchange Growth Market. Its lead pipeline is CBP501, an 'immune ignition agent' being developed for the treatment of pancreatic cancer and other solid tumors. Canbas also has a second pipeline, CBS9106, a reversible XPO1 inhibitor, and is conducting basic research to generate next-generation clinical candidates such as CBT005. The company pursues a hybrid business model, combining partnerships with larger pharmaceutical companies for some programs while advancing its own late-stage clinical development for others. Canbas has received orphan drug designations from the US FDA and the European Medicines Agency for CBP501 in mesothelioma and pancreatic cancer, respectively.

Canbas Co., Ltd. was founded in 2000 as a drug-discovery biopharmaceutical company focused on anticancer agents. The company is headquartered in Numazu, Shizuoka Prefecture, Japan. In 2002, it moved its headquarters and research laboratory to Numazu and established an animal experiment facility. In 2005, Canbas began a Phase 1 clinical trial of CBP501 as a single agent in the United States. In 2006, a Phase 1 trial of CBP501 in combination with cisplatin started in the US. In 2007, Canbas entered a co-development agreement with Takeda Pharmaceutical Company for CBP501 and backup compounds. In 2008, Phase 2 trials of CBP501 in combination with cisplatin and pemetrexed began in the US for malignant pleural mesothelioma and non-small cell lung cancer. In 2009, Canbas listed on the Tokyo Stock Exchange Mothers Market. In 2010, the company consolidated its headquarters, research institute, and animal facility at its current location in Numazu and terminated the co-development agreement with Takeda. In 2012, CBP501 met its primary endpoint in a Phase 2 trial for malignant pleural mesothelioma, and received orphan drug designation from the US FDA for mesothelioma. In 2013, preliminary results from a Phase 2 trial in non-small cell lung cancer were announced. In 2014, Canbas signed a license agreement with Stemline Therapeutics for CBS9106. In 2016, Stemline began a Phase 1 trial of CBS9106 (SL-801) in solid tumors. In 2017, a Phase 1b trial of CBP501, cisplatin, and nivolumab (Opdivo) began. In 2018, the license agreement with Stemline for CBS9106 was amended to expand the territory to worldwide including Japan, China, Taiwan, and South Korea. In 2020, Canbas announced completion of enrollment in the expansion phase of the Phase 1b trial of CBP501 in pancreatic cancer and presented data at ASCO. In 2021, a Phase 2 trial of CBP501 for third-line pancreatic cancer was authorized by the US FDA and the first patient was enrolled. In 2022, Canbas transitioned from the TSE Mothers Market to the Growth Market, and extended its joint research agreement with the University of Tokyo. In 2023, Canbas obtained a patent from the Japan Patent Office for an IDO/TDO inhibitor. In 2024, CBP501 received orphan drug designation from the European Medicines Agency, and the US FDA approved the start of a Phase 2b clinical trial. In 2025, the license agreement with Stemline for CBS9106 was terminated, returning all rights to Canbas.

• Company founded

• Headquarters and research laboratory moved to Numazu, Shizuoka; animal experiment facility established

• Phase 1 clinical trial of CBP501 single agent started in the US

• Phase 1 trial of CBP501 in combination with cisplatin started in the US

• Co-development agreement with Takeda Pharmaceutical for CBP501 and backup compounds

• Phase 1 trial of CBP501, cisplatin, and pemetrexed started in the US

• Phase 2 trial of CBP501, cisplatin, and pemetrexed for malignant pleural mesothelioma started in the US

• Phase 2 trial of CBP501, cisplatin, and pemetrexed for non-small cell lung cancer started in the US

• Listed on the Tokyo Stock Exchange Mothers Market

• Co-development agreement with Takeda Pharmaceutical terminated

• Headquarters, research institute, and animal facility consolidated at current location in Numazu

• CBP501 received orphan drug designation from US FDA for mesothelioma

• CBP501 met primary endpoint in Phase 2 trial for malignant pleural mesothelioma, announced at ASCO

• Preliminary results of Phase 2 trial for non-small cell lung cancer announced

• License agreement with Stemline Therapeutics for CBS9106

• Stemline started Phase 1 trial of CBS9106 (SL-801) in solid tumors

• Phase 1b trial of CBP501, cisplatin, and nivolumab (Opdivo) started

• License agreement with Stemline for CBS9106 amended to expand territory to worldwide

• CBP501 Phase 1b trial data presented at ASCO; enrollment completed for pancreatic cancer expansion phase

• Completion of dosing in Phase 1b trial of CBP501 and preliminary efficacy data for MSS colorectal cancer announced

• US FDA authorized Phase 2 trial of CBP501 for third-line pancreatic cancer

• Phase 2 trial site for CBP501 opened

• First patient enrolled in Phase 2 trial of CBP501

• Stemline completed Phase 1 trial of CBS9106 (SL-801) in solid tumors

Clinical-stage biopharmaceutical company specializing in anticancer drug discovery and development.

• CBP501

  An 'immune ignition agent' anticancer drug candidate. Being developed for pancreatic cancer, mesothelioma, and other solid tumors. Received orphan drug designations from US FDA (mesothelioma) and EMA (pancreatic cancer).

• CBS9106

  A reversible XPO1 inhibitor. Licensed to Stemline Therapeutics (as SL-801, generic name Felezonexor) from 2014 to 2025; rights returned to Canbas in 2025.

• CBT005

  A next-generation immune-system anticancer compound showing promising animal data; preparing for preclinical trials.

1. 1株式会社キャンバスcanbas.co.jp
2. 2沿革 | 株式会社キャンバスcanbas.co.jp
3. 3ご挨拶 | 株式会社キャンバスcanbas.co.jp
4. 4企業情報 | 株式会社キャンバスcanbas.co.jp
5. 5Canbas Co., Ltd. (Japan) - Wikidatawikidata.org